Nell, former SVP Head Corporate Strategy & Business Development at Casebia Therapeutic and Tisch, former COO of Synthego, will bring 30 plus years of collective experience in the life sciences market to Mammoth
Mammoth Biosciences, the company developing the next generation of CRISPR products, today announced the addition of two key members to its executive team. The expansion of the team supports Mammoth’s growth in the life sciences market as the company continues to discover and democratize access to CRISPR systems.
Peter Nell, Ph.D. joins Mammoth Biosciences as Chief Business Officer and Head of Therapeutics. In this role, he’ll leverage his vast business development and corporate strategy experience from Casebia Therapeutics and Bayer HealthCare to scale Mammoth’s CRISPR offering. A chemist by training, Peter is listed as co-inventor on more than 45 patents, and author or co-author of several scientific publications and book contributions in the biomedical field.
Peter remarks, “During my time at Casebia, the company addressed various challenges of CRISPR-based therapeutics, which allowed us to move some of the most advanced projects into the preclinical phase in an extremely short timeframe. At Mammoth, I look forward to bringing our novel and proprietary CRISPR systems to market to make an impact on healthcare and beyond.”
Ted Tisch joins as Chief Operations Officer after four years at Synthego Corporation where he grew the company from 18 to 250 employees. At Synthego, he established the product development, manufacturing operations, and commercial program for two CRISPR-based product lines, CRISPRevolution and Engineered Cells. Previously, Ted served as Vice President-General Manager for the $200M Protein Function Division at Bio-Rad Laboratories with responsibilities spanning bioprocessing, multiplex immunoassay, imaging, and life science education programs.
“The founding team at Mammoth is a group of scientific geniuses,” Ted asserts. “It’s an honor to be working alongside Berkeley and Stanford PhDs who were recognized by Forbes 30 Under 30, while also having guidance from CRISPR pioneer Jennifer Doudna. I’m excited to share my business experience and grow the company.”
To learn more about joining Mammoth’s team visit https://mammoth.bio/join-us
About Mammoth Biosciences
Mammoth Biosciences is harnessing the diversity of nature to power the next-generation of CRISPR products. Through the discovery of novel CRISPR systems, the company is enabling the full potential of its platform to read and write the code of life. Mammoth aims to democratize disease detection with an easy and affordable point-of-care test that allows real-time and simultaneous detection of multiple conditions. By leveraging its internal research and development and exclusive licensing to Cas12, Cas13 and Cas14 from the University of California, Mammoth can provide enhanced tools for life science research from healthcare to agriculture, environmental monitoring, biodefense and more. Based in San Francisco, Mammoth Biosciences is co-founded by CRISPR pioneer Jennifer Doudna and led by principal founders Trevor Martin, Janice Chen, and Lucas Harrington. The firm is backed by top institutional investors including Mayfield, NFX, and 8VC.